Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
Go back to Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 1.79 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.79 | 52 Week High | $19.41 | |||
| Open | $1.79 | 52 Week Low | $4.83 | |||
| Day High | $1.79 | P/E | N/A | |||
| Day Low | $1.79 | EPS | $-2.74 | |||
| Volume | 1,805 | |||||
